Clinical trials: CRP
Hypercholesterolemia With Type2DM
Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia
A randomized, open label, dose titration study to evaluate the efficacy and safety of Pitavastatin compared to atorvastatin in Type 2 Diabetes Mellitus with hypercholesterolemia
- Trial name
- ESPRIT (NCT00889226)
- Testing
- Pitavastatin, Atorvastatin
- Volunteers
- 161 people
- Sponsor
- JW Pharmaceutical
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism
The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of selective Vitamin D Receptor Activator's as it is prescribed in the normal clinical setting and according…
- Trial name
- NCT01149291
- Where
- 22 sites in Turkey (Türkiye)
- Volunteers
- 511 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable…
- Trial name
- TBRIDGE-CV (NCT07487363)
- Testing
- TB-500
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Hudson Biotech
Inflammation, Infections
A Performance Evaluation of the LumiraDx Point of Care CRP Assay
In patients with symptoms of infection, tissue injury and inflammatory disorders the study will evaluate agreement between the CRP measurements from the LumiraDx POC CRP assay and the Siemens Dimension Xpand Plus CRP assay, as an…
- Conditions
- Inflammation, Infections, Tissue Injury
- Trial name
- REACT (NCT05180110)
- Testing
- Venepuncture, Fingerstick
- Where
- 3 sites in United Kingdom
- Volunteers
- 79 people
- Sponsor
- LumiraDx UK Limited
Immune Response
LIFEHOUSE: Description of the Tent Bucket -Immune Support
This immune support program will be an extension to the existing LIFEHOUSE program. Essential employees in Gig Harbor, WA; Colonial Heights, VA; Lenexa, KS, and Santa Fe Springs, CA, will be offered complimentary supplementation…
- Trial name
- LIFEHOUSE (NCT04734288)
- Testing
- Vit.D3 5000 IU, Immune Active
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Embolism and Thrombosis, Infection
Evaluation of the LumiraDx Point of Care D-Dimer and CRP Tests
A Multicenter Study Conducted to Evaluate the Agreement between Fingerstick Whole Blood, Venous Whole Blood and Plasma Determined on the LumiraDx Point of Care D-Dimer and Point of Care CRP Tests to Results on the Reference…
- Conditions
- Embolism and Thrombosis, Infection, Inflammation
- Trial name
- NOVEL-3 (NCT04375982)
- Testing
- Venepuncture, Fingerstick
- Where
- 4 sites in United States
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Respiratory Tract Infections, Urinary Tract Infections
TriVerity in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
This study will analyze gene expression and other laboratory data from biological samples collected from participants with suspected respiratory, urinary, intra-abdominal, and/or skin \& soft tissue infections; or suspected…
- Conditions
- Respiratory Tract Infections, Urinary Tract Infections, Intra-Abdominal Infections, Skin and Soft Tissue Infection
- Trial name
- SEPSIS-SHIELD (NCT04094818)
- Testing
- TriVerity
- Where
- 26 sites in United States, Greece
- Volunteers
- 1,441 people
- Sponsor
- Inflammatix
C-Reactive Protein
A Study of Single and Multiple Doses of LY5625573 in Healthy Participants, Including Japanese and Chinese Populations, and Participants With Inflammation (High C-Reactive Protein)
The purpose of this study is to learn if LY5625573 is safe and how well it is tolerated in healthy participants, including Japanese and Chinese participants, and in participants with high levels of a marker for inflammation…
- Trial name
- NCT07867340
- Testing
- LY5625573, Midazolam
- Where
- 3 sites in United States, Singapore
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
hsCRP
Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population
An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and…
- Trial name
- CALLISTO (NCT00819273)
- Where
- 10 sites in South Korea
- Volunteers
- 1,700 people
- Sponsor
- AstraZeneca
Atherosclerosis
Integrated Biomarker And Imaging Study - 2
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and tolerability.
- Trial name
- NCT00268996
- Testing
- SB-480848
- Where
- 26 sites in Austria, Belgium and 9 more
- Volunteers
- 336 people
- Sponsor
- GlaxoSmithKline
Atherosclerosis, Cardiovascular Disease
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab compared with placebo in adults who have elevated hsCRP and at increased…
- Conditions
- Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension
- Trial name
- CLARITY-CRP (NCT07783802)
- Testing
- Clazakizumab
- Where
- 46 sites in United States, Argentina and 2 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.
- Trial name
- NCT03233230
- Testing
- M2591 25 mg QD, M2951 75 mg QD, M2951 50 mg BID
- Where
- 97 sites in United States, Argentina and 10 more
- Volunteers
- 390 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Covid19
CRP-Apheresis for Attenuation of Pulmonary, MYocardial and/or Kidney Injury in COvid-19
The 'CAPMYKCO' study is a randomized controlled, open-label, single center proof of concept trial. The aim of this study is to evaluate whether a CRP-apheresis in addition to the current standard therapy is intended to mitigate…
- Trial name
- CAPMYKCO (NCT04898062)
- Testing
- CRP-apheresis
- Where
- 4 sites in Germany
- Sponsor
- Pentracor GmbH
Stress Resilience, Systemic Inflammation
Oral Supplementation With 1 mg of KGA-10 Daily (a Novel Environmentally-derived Mycolicibacterium) for Stress, Sleep, and Inflammation
The goal of this clinical trial is to learn if a novel strain of heat-killed Mycolicibacterium that is being considered by the International Code of Nomenclature of Prokaryotes (ICNP) as candidate species and type strain…
- Conditions
- Stress Resilience, Systemic Inflammation, General Wellbeing, Sleep Quality
- Trial name
- NCT07604038
- Testing
- Mycolicibacterium petrae KGA-10 (heat-killed)
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Kioga Inc.
Stroke, Ischemic
CASTRO1 - Study on CRP Apheresis After Ischemic Stroke
CASTRO1 is a study to investigate the reduction of C-reactive protein (CRP) by therapeutic apheresis (CRP-apheresis) in patients after primary treatment of ischemic stroke.
- Trial name
- CASTRO1 (NCT04417231)
- Testing
- CRP apheresis
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- Pentracor GmbH
Elevated High-sensitivity C-Reactive Protein (hsCRP)
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of…
- Trial name
- NCT00239681
- Testing
- Rosuvastatin
- Where
- 856 sites in United States, Argentina and 25 more
- Volunteers
- 17,802 people
- Sponsor
- AstraZeneca
Atherosclerosis
Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease
This study is a, randomized, double-blind, placebo-controlled phase 2a trial evaluating the potential of MLN1202 to reduce circulating levels of C-reactive protein (CRP)in patients with risk factors for Atherosclerotic…
- Trial name
- NCT00715169
- Testing
- MLN1202
- Volunteers
- 108 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive, Chronic Obstructive Pulmonary Disease (COPD)
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)
This is a 28-day, placebo controlled clinical study assessing the safety, tolerability anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD (Chronic Obstructive Pulmonary Disease).
- Trial name
- NCT00144859
- Testing
- SB681323
- Where
- 17 sites in Denmark, Finland and 3 more
- Volunteers
- 82 people
- Sponsor
- GlaxoSmithKline
Sepsis, SIRS
Performance Evaluation of the Nanomix eLab® CRP, PCT, and LAC Assays With the Nanomix eLab System
The performance of the eLab C-Reactive Protein, Procalcitonin, and Lactate Assays will be demonstrated during a method comparison study in which venous whole blood and plasma samples are used.
- Trial name
- NCT03876535
- Testing
- Nanomix eLab® System molecular diagnostic test (non-interventional)
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Nanomix
Rheumatoid Arthritis (RA)
Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Prospective, post-marketing, multi-center, open-label study to explore if the initiation of adalimumab could influence grey-scale (GS) and power Doppler (PD) ultrasonographic (US) score using 36-joint plus 4-tendon scoring…
- Trial name
- NCT02786563
- Where
- 4 sites in China
- Sponsor
- AbbVie